Reimbursement Scheme Forxiga® (dapagliflozine) 10 mg for the treatment of HFpEF (LVEF >40%)
The health insurer does not yet fully reimburse Forxiga® (dapagliflozin) 10 mg for the treatment of HFpEF (LVEF >40%). The manufacturer of this medicine has therefore asked TBR Nederland to reimburse the total costs of the Personal Contribution to the patient.
The Personal Contribution for Forxiga® (dapagliflozin) 10 mg that is charged to the patient by the pharmacy will be fully reimbursed from February 13, 2023.
Who can submit a claim?
Only patients or their caregivers can claim the Personal Contribution Forxiga® (dapagliflozin) 10 mg online or by post. Online will be the fastest option.
NL-10662 prod. 01/2023